Omnibus VI Just Rewrote the Clock on Banned Cosmetic Ingredients

Sep 1

4 min read

Keywords: Omnibus VI cosmetics · CMR substances EU cosmetics · Regulation (EC) 1223/2009 · EU trilogue agreement cosmetics · cosmetic ingredient ban deadlines · CLP classification cosmetics

A political agreement most brands haven't clocked yet

If your brand has been treating Omnibus VI as background noise — another EU simplification package moving slowly through Brussels — the political agreement reached on 16 June 2026 is the moment to start paying closer attention. Negotiators from the European Parliament and the Council closed trilogue talks on the package that amends the Classification, Labelling and Packaging (CLP) Regulation, the Cosmetics Regulation (EC) No 1223/2009, and the Fertilising Products Regulation. We covered Omnibus VI back in April, when the European Parliament adopted its negotiating position with 540 votes in favour. This is the sequel, and for cosmetics specifically, it does something the Commission's original July 2025 proposal didn't: it makes the ban-to-shelf timeline for prohibited ingredients considerably shorter, and it closes an exemption route several brands were quietly relying on.

The mechanism this actually runs on

None of this happens in a vacuum. Under Regulation (EC) No 1223/2009, once a substance receives a harmonised classification as carcinogenic, mutagenic or toxic to reproduction (CMR, categories 1A, 1B or 2) under the CLP Regulation, it becomes automatically prohibited for use in cosmetic products under Article 15 — unless the Commission grants a specific derogation following a favourable SCCS safety opinion. This isn't a one-off rule Cláritas is flagging for this ingredient or that one; it's the standing mechanism behind nearly every cosmetic ingredient ban of the last decade, including the Omnibus acts that keep arriving in sequence (VI now in trilogue, VII and VIII already in force, IX in preparation). Once a ban is triggered, two separate deadlines always apply: one for placing on the market — the first supply by a manufacturer or importer — and one for making available on the market, which covers every subsequent supply, including a retailer selling through existing stock. The gap between those two dates is what determines how long product already on shelves can keep selling.

What the June agreement actually changes

The Commission's original proposal gave brands 12 months to stop placing a newly banned CMR substance on the market, and 24 months before retailers had to stop making it available. The agreed text cuts both of those windows in half, and adds two changes that matter just as much:

6 months to stop placing the product on the market (down from the Commission's proposed 12).
12 months to stop making it available — the effective sell-through deadline (down from 24).
No exemption based on route of exposure: a CMR classification driven purely by oral or inhalation toxicity data can still trigger a cosmetics ban or derogation review, even where the hazard has nothing to do with skin contact.
A new, explicit 12-month deadline to file a derogation request, running from the date of the CMR classification — previously, that window wasn't clearly defined.
The obligation to notify the Commission before marketing nanomaterial-containing cosmetics is kept, but the six-month advance-notice buffer from the original 2009 text is removed.

Taken together, this is a package that trades administrative simplification (the Commission's stated goal) for materially less reaction time once an ingredient is classified — the opposite of what "simplification" usually implies for the brands actually holding stock.

Where brands get this wrong

Three misreadings come up constantly when this news reaches indie brands secondhand. First, treating Omnibus VI as if it were already law: 16 June was a provisional political agreement between negotiators, not a published regulation, and it still needs formal endorsement by both the Council and Parliament before it exists as a legal text. Second, collapsing the two deadlines into one: the six-month clock governs new production and import, not the stock already sitting in a warehouse or on a retailer's shelf — brands that assume they have a full year to sell through are reading the wrong number. Third, assuming an oral- or inhalation-only CMR classification is irrelevant to a leave-on face cream — the agreement explicitly closes that door, and it's the kind of detail that only shows up if someone is reading the classification, not just the headline.

What happens next, and why this outlasts the news cycle

The provisional agreement still needs formal endorsement from Coreper and the Parliament's committee, a plenary vote, legal-linguistic revision, and publication in the Official Journal before it enters into force — a process the co-legislators are aiming to complete "in the course of 2026," with different provisions likely to carry staggered application dates. None of that changes the part worth internalising now: the placing-on-the-market / making-available two-tier deadline structure isn't specific to this package. It is how every future ingredient ban under the Cosmetics Regulation will work, including whatever Omnibus VII eventually finalises. Learning to read that structure — and where a substance sits in ECHA's classification pipeline before it ever reaches Annex II — is the transferable skill, not the memorised date.

Before the text is formally adopted

Identify which of your formulations contain ingredients with an open or pending CLH (harmonised classification) proposal at ECHA — not just those already listed in Annex II.
Ask suppliers directly whether any raw material has ever been subject to a CMR classification proposal, not only whether it is currently restricted.
If a substance you use is newly CMR-classified once Omnibus VI is in force, mark two dates immediately: six months out (placing on the market) and twelve months out (sell-through).
If a derogation is realistically an option for your use case, build the filing into your calendar the day a classification is proposed — not the day it's confirmed.
Update your Product Information File monitoring process to track CLP classification status as a standing checklist item, not a one-time review.

Cláritas Regulatory tracks Omnibus VI, and the CLP classifications behind it, for independent brands that don't have an in-house regulatory affairs team watching Brussels full time. If your formulation depends on an ingredient with an open classification proposal, get in touch.